Charles Link
Founder at Syncromune, Inc.
Net worth: - $ as of 29/04/2024
Profile
Charles J.
Link was the founder of NewLink Genetics Corp.
(founded in 1999) where he held the titles of Chairman, Chief Executive & Scientific Officer from 2003 to 2019.
He was also the founder of Central Iowa Hospital Corp.
(founded in 1995) where he served as a Director from 1995 to 2003.
In addition, he is the founder of Syncromune, Inc. (founded in 2020) and currently holds the title of Executive Chairman.
Dr. Link's current job(s) include being a Director at NovaScan, Inc. since 2020, a Director at ImmunSYS, Inc., and a Director at Viewpoint Molecular Targeting, Inc. since 2021.
His former job(s) include being the Chairman & Chief Executive Officer of BioProtection Systems Corp.
from 2005 to 2009 and an Independent Director at QSAM Biosciences, Inc. from 2021 to 2024.
He also held the title of Chief Executive & Scientific Officer at Lumos Pharma, Inc.Dr. Link's education includes an undergraduate degree from Stanford University and a doctorate from Stanford University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
-.--% | 01/05/2024 | 0 ( -.--% ) | - $ | 29/04/2024 |
Charles Link active positions
| Companies | Position | Start |
|---|---|---|
ImmunSYS, Inc.
 ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. | Director/Board Member | - |
NovaScan, Inc.
 NovaScan, Inc. Medical SpecialtiesHealth Technology NovaScan, Inc. engages in the development of a technology that electrically images objects. Its technology measures the electrical properties of materials. The firm focuses on breast cancer detection. The company was founded in 2001 by Larry Wells and William Gregory and is headquartered in Chicago, IL. | Director/Board Member | 31/12/2019 |
Viewpoint Molecular Targeting, Inc.
 Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA. | Director/Board Member | 17/05/2021 |
Syncromune, Inc.
 Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | Founder | 30/11/2020 |
Former positions of Charles Link
| Companies | Position | End |
|---|---|---|
| QSAM BIOSCIENCES, INC. | Director/Board Member | 01/05/2024 |
| LUMOS PHARMA, INC. | Chief Executive Officer | 02/08/2019 |
| LUMOS PHARMA, INC. | Chief Executive Officer | 02/08/2019 |
BioProtection Systems Corp.
 BioProtection Systems Corp. BiotechnologyHealth Technology Part of Lumos Pharma, Inc., BioProtection Systems Corp. is a company that manufactures biological products. The company is based in Ames, IA. | Chairman | 31/12/2008 |
| Central Iowa Hospital Corp. | Founder | 31/12/2002 |
Training of Charles Link
| Stanford University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| LUMOS PHARMA, INC. | Health Technology |
| Private companies | 8 |
|---|---|
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
BioProtection Systems Corp.
BioProtection Systems Corp. BiotechnologyHealth Technology Part of Lumos Pharma, Inc., BioProtection Systems Corp. is a company that manufactures biological products. The company is based in Ames, IA. | Health Technology |
| Central Iowa Hospital Corp. | |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. | Health Technology |
NovaScan, Inc.
NovaScan, Inc. Medical SpecialtiesHealth Technology NovaScan, Inc. engages in the development of a technology that electrically images objects. Its technology measures the electrical properties of materials. The firm focuses on breast cancer detection. The company was founded in 2001 by Larry Wells and William Gregory and is headquartered in Chicago, IL. | Health Technology |
QSAM Biosciences, Inc.
 QSAM Biosciences, Inc. Chemicals: AgriculturalProcess Industries QSAM Biosciences, Inc. engages in the provision of nuclear medicines for the treatment of cancer and related diseases and conditions. It also focuses on the development of its licensed radiopharmaceutical drug candidate, Samarium-153-DOTMP or CycloSam. The company was founded by Christopher M. Nelson, Douglas R. Baum and C. Richard Piazza on August 26, 2004 and is headquartered in Austin, TX. | Process Industries |
Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA. | Commercial Services |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | Health Technology |
- Stock Market
- Insiders
- Charles Link
